Literature DB >> 3855363

Large granular lymphocytes have a promoting activity on human peripheral blood erythroid burst-forming units.

V Pistoia, R Ghio, A Nocera, A Leprini, A Perata, M Ferrarini.   

Abstract

Peripheral blood mononuclear cells were fractionated according to the expression of a variety of surface markers, and the fractions obtained were tested for erythroid burst-forming unit (BFU-E) colony formation. BFU-Es were detected in the HLA-DR+ non-T cell fraction, but gave rise to optimum colony numbers only in the presence of a nonadherent, relatively radioresistant cell. This accessory cell was found among the HLA-DR- non-T, non-B cells, a fraction that was particularly enriched in large granular lymphocytes (LGLs). Experiments carried out to assess directly the surface markers of the accessory cell revealed an FcR+, OKM1+, Leu 7+, Leu 11+, OKT4-, OKT8- surface phenotype, which is consistent with that of the majority of LGLs. Peripheral blood LGLs, purified by Percoll density gradient, proved very efficient in promoting optimal BFU-E colony formation. All of these results indicate that LGLs have a potent erythroid burst-promoting activity. Such activity is probably mediated through the release of soluble factors, as shown by the observation that LGL culture supernatants were as effective as LGLs in sustaining colony formation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3855363

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Characterization of EN4 monoclonal antibody: a reagent with CD31 specificity.

Authors:  V L Burgio; S Zupo; S Roncella; M Zocchi; L P Ruco; C D Baroni
Journal:  Clin Exp Immunol       Date:  1994-04       Impact factor: 4.330

2.  Lymphocytosis of large granular lymphocytes associated with anemia and neutropenia: proof of monoclonality of the LGL-population, but benign clinical course.

Authors:  S Serke; A Neubauer; D Huhn
Journal:  Klin Wochenschr       Date:  1989-06-01

3.  Inhibition of pluripotent hematopoietic stem cells of bone marrow by large granular lymphocytes.

Authors:  T Barlozzari; R B Herberman; C W Reynolds
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

4.  Cell-mediated cytotoxicity in Down syndrome: impairment of allogeneic mixed lymphocyte reaction, NK and NK-like activities.

Authors:  D Montagna; R Maccario; A G Ugazio; L Nespoli; E Pedroni; P Faggiano; G R Burgio
Journal:  Eur J Pediatr       Date:  1988-10       Impact factor: 3.183

5.  Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.

Authors:  L J Levitt; A Nagler; F Lee; J Abrams; M Shatsky; D Thompson
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

6.  Establishment of Tac-negative, interleukin-2-dependent cytotoxic cell lines from large granular lymphocytes (LGL) of patients with expanded LGL populations.

Authors:  V Pistoia; A J Carroll; E F Prasthofer; A B Tilden; K S Zuckerman; M Ferrarini; C E Grossi
Journal:  J Clin Immunol       Date:  1986-11       Impact factor: 8.317

7.  Identification of three accessory cell populations in human bone marrow with erythroid burst-promoting properties.

Authors:  D C Linch; J M Lipton; D G Nathan
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

8.  Decay-accelerating factor is present on paroxysmal nocturnal hemoglobinuria erythroid progenitors and lost during erythropoiesis in vitro.

Authors:  J G Moore; M M Frank; H J Müller-Eberhard; N S Young
Journal:  J Exp Med       Date:  1985-10-01       Impact factor: 14.307

9.  Production of hematopoietic colony-stimulating factors by human natural killer cells.

Authors:  M C Cuturi; I Anegón; F Sherman; R Loudon; S C Clark; B Perussia; G Trinchieri
Journal:  J Exp Med       Date:  1989-02-01       Impact factor: 14.307

Review 10.  Biology of natural killer cells.

Authors:  G Trinchieri
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.